Vitae Pharmaceuticals, Inc., an transputer ascertainment and growth company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutic companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the care of insulin-dependent insulin-dependent insulin-dependent diabetes and metabolic syndrome-related diseases in a cunning especially of nations for a common cause.
anschluss with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small fragment inhibitor of 11beta-HSD-1 into Phase I clinical trials.

More: - Brought to my attention by